ENVB Overview

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its discovery and development platform, the Psybrary platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, the Company seeks to develop a robust intellectual property portfolio of drug candidates. Its lead molecule, EB-003, is a neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. The Company is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other Psybrary platform drug candidates to third-party licensees and advancing non-competitive market strategies for patient care.

Wall Street analysts forecast ENVB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENVB is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Enveric Biosciences Inc revenue for the last quarter amounts to -1.87M USD, decreased -10.04

Enveric Biosciences Inc. EPS for the last quarter amounts to USD, decreased

Enveric Biosciences Inc (ENVB) has 5 emplpoyees as of March 12 2026.

Today ENVB has the market capitalization of 2.74M USD.